HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ciba Tinosorb sunscreens

This article was originally published in The Rose Sheet

Executive Summary

Ciba Specialty Chemicals should initiate new drug application process for UVA/UVB filters Tinosorb M and Tinosorb S to obtain approval as OTC sunscreens, FDA says in July 15 letter to supplier. Letter denies Ciba's May 21 time and extent application to introduce ingredients in the U.S. based on foreign marketing experience. Ciba has "not demonstrated that the ingredients have been marketed for a material time and a material extent," FDA says, noting under its regulations, ingredients must be marketed for "a minimum of five continuous years in the same country and in sufficient quantity." Ciba sells the ingredients in more than five countries but could only provide two and a half years of continuous use data. TEA was adapted from citizen petition filed by the company Sept. 5, 2000 seeking monograph status for the ingredients (1"The Rose Sheet" Sept. 11, 2000, p. 9). FDA decision is apparently first refusal of TEA for sunscreen ingredients...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

RS010492

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel